Asthma in ChildrenNCT03390556
Promoting Partnership and Improving Self-Management for Children With Persistent Asthma
A study testing Nurse-delivered education in people with Asthma in Children, run by University of Rochester at 1 site in United States.
Trial summary
The goal of this study is to evaluate a pilot of clinic-based intervention of asthma education. After a scheduled outpatient encounter for well-child care or asthma care has concluded, a pediatric nurse will teach participants (children and their caregivers) about asthma, provide clearly written information about how… Read more about this study
- Who is it for?
- Ages 7 to 14 years
- Conditions the study is for
- Asthma in Children
- What is being tested?
- Nurse-delivered education
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 44 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Jun 2018to 30 Jun 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 to 14 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Physician diagnosis of asthma, based on review of medical records.
- Uncontrolled asthma consistent with National Heart, Lung, and Blood Institute (NHLBI) guidelines, with at least 1 of the following based on caregiver report:
- If the child is 7-11 years old: i. An average of >2 days per week with asthma symptoms ii. >2 days per week with rescue medication use iii. >2 days per month with nighttime symptoms iv. ≥2 episodes of asthma during the past year that have required systemic corticosteroids b. If the child is 12-14 years old: i. An average of >2 days per week with asthma symptoms ii. >2 days per week with rescue medication use iii. Nighttime symptoms 1-3 times per week iv. ≥2 episodes of asthma during the past year that have required systemic
- The child must have a current prescription (within the past year) of an inhaled asthma controller medication, such as an inhaled corticosteroid (ICS), based on review of electronic medical records.
- The child/adolescent is between ≥7 and ≤14 years old.
- The child/adolescent is insured by Medicaid or Medicaid managed care program.
Who cannot join
- An inability to speak and understand English. Parents and children with low literacy / health-literacy skills will be eligible, as survey instruments will be administered verbally and educational materials will be designed for low-literacy populations.
- No access to a working phone for follow-up, including care coordinator calls and the final follow-up survey.
- Another significant medical condition identified in the child's medical record that could interfere with assessment of asthma control, including Cystic Fibrosis, congenital heart disease, or other chronic pulmonary disease.
- A diagnosed developmental condition (e.g. Autism spectrum disorder or significant developmental delay) identified in the child's medical record that could impact the transition of responsibility for inhaled asthma medications from caregiver to child.
- If the child or family is currently enrolled in a study conducted by The Preventive Care Program for Urban Children with Asthma (led by Dr. Jill Halterman).
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Rochester Medical Center
Rochester, New York, 14642
About this study
Official title: Promoting Partnership and Improving Self-Management for Children With Persistent Asthma: A Pilot Program of Clinic-Based Asthma Education and Medication Labeling
The goal of this study is to evaluate a pilot of clinic-based intervention of asthma education. After a scheduled outpatient encounter for well-child care or asthma care has concluded, a pediatric nurse will teach participants (children and their caregivers) about asthma, provide clearly written information about how to manage asthma, and discuss how to manage asthma at home with cooperation between caregivers and children. Families will also receive current asthma prescriptions in clinic, and colored labels will be attached to medications in order to match the color scheme of asthma action plans (green labels for controller medications, red labels for rescue medications). Families will be followed for 3 months after the first clinic visit, including a follow-up visit in clinic 1 month later and a follow-up telephone call 3 months after starting. The nurse will reinforce key educational points and review medication use at the follow-up clinic visit. Families will also be invited to complete an additional in-depth interview following the 1 month clinic follow-up. The investigator hypothesizes that knowledge, self-efficacy, and reported adherence with asthma medications will increase for both caregivers and children/adolescents following the intervention and labeling of delivered medications. In addition, the investigator hypothesizes that children/adolescents will have more symptom free days and improved control following the intervention.
Read the detailed description
Study Design:
The investigators propose a clinic-based intervention of asthma education and medication labeling to promote medication knowledge and self-efficacy for adherence among both caregivers and children. Approximately 40 children with uncontrolled persistent asthma and their caregivers will be enrolled prior to outpatient visits for asthma care (well child care or asthma-specific visits; total of 80 participants). After the scheduled encounter with a provider has concluded, enrolled dyads will receive an intervention of nurse-delivered asthma education and medication labeling. Dyads will then be followed prospectively for 3 months after the index visit. This follow-up period will include a clinic-based follow-up with a repeat of the intervention (1 month after enrollment, consistent with the follow-up interval suggested by national guidelines for uncontrolled asthma) and a second follow-up by telephone (2 months after clinic follow-up). Families will be invited to complete an additional in-depth interview following the 1 month clinic follow-up.
Subjects and Setting:
Children and adolescents 7-14 years of age will be screened for eligibility at a single ambulatory care location: the Golisano Children's Hospital Pediatric Practice, a National Committee for Quality Assurance (NCQA) accredited patient centered medical home (PCMH) in urban Rochester, New York. The investigators plan to enroll a convenience sample of 40 dyads of caregivers/children (total of 80 subjects) over an 8 month period. Children and adolescents will be enrolled equally from two age-based categories (7-10 years, 11-14 years). The range of child/adolescent ages is intended to select families with a range of shared responsibility for asthma medication use between the caregiver and child/adolescent. Some children independently use medications as early as six years old. On average, children bear half of the responsibility for controller medication use by age 11 years and have more responsibility than caregivers after age 13 years. Given these data, the specified age-based sub-groups are structured to reflect family dynamics in which children have <50% of responsibility for medications (7-10 years old) and ≥50% of responsibility for medications (11-14 years).
Study Procedures:
Screening Procedures: Screening will occur in a rolling fashion from January 2018 through August 2018. The investigators will identify potentially eligible children through a weekly review of pediatric clinic patients ages 7-14 years old who are (1) scheduled for well-child or asthma care over the following week, (2) have persistent asthma on their problem list, (3) have a current (within the last year) prescription for an inhaled controller medication, and (4) are covered by Medication or a Medicaid managed care program. After the reports are furnished, Dr. Frey will conduct a brief review of the patient's chart to determine whether key eligibility criteria are met (no known language barriers, no other significant medical or developmental conditions). Remaining eligibility criteria (i.e. determination of persistent/uncontrolled asthma per NHLBI guidelines) will be assessed during a single screening phone call prior to the scheduled visit, or by approaching caregivers at the time of scheduled visits if we are unable to reach caregivers by phone.
Baseline Assessment: The baseline survey assessment will be conducted following enrollment by the team research assistant within a private space in the clinic. All survey instruments will be available in English, and questions will be read aloud to the caregiver and child. If the baseline semi-structured survey is not completed before the provider encounter, caregivers will be given the option to complete the baseline either (a) before leaving clinic, or (b) over the telephone; completion in the clinic will be preferred so that children/adolescents can be separately interviewed in the presence of their caregivers.
Medication Selection and Delivery: Providers will be notified that their patients are enrolled into the program, and will be tasked with determining whether any changes in daily controller medications are indicated. The provider will electronically transmit prescriptions for both rescue and controller medications to the Strong Outpatient Pharmacy, located within the same building as the Pediatric Practice. All asthma prescriptions will be filled at this pharmacy during the trial in order to ensure that medications will be available for labeling in clinic, and parents will be informed of this during the consent process. The research assistant will call the pharmacy to notify them of new prescriptions; once these asthma prescriptions are filled, they pharmacy will send them to the Pediatrics Practice via the institution's pneumatic tube system. Any prescription medications that are not directly related to asthma management (including adjuvant therapies for allergic rhinitis) would be sent to the pharmacy of their choosing for normal processing and patient pick-up.
Nurse-delivered Education: The nurse will give the educational intervention after the provider encounter concludes. Nurses will be trained in intervention delivery and national asthma guidelines by Dr. Frey and Cindy Trubisky, Senior Director of Health Education for the American Lung Association (ALA) in Rochester, NY. This intervention will be directed toward both the caregiver and the child.
- The nurse will give the parent and child a brief, scripted overview of asthma, and discuss asthma control, asthma triggers, and indications for using inhaled controller vs. rescue medications.
- Parents will be given simple, written information about asthma and asthma management designed for low health-literacy audiences, specifically written at or below 6th grade reading levels, including:
- Information on appropriate metered dose inhaler (MDI)/ spacer technique
- An updated asthma action plan, with clear indications for when to use each inhaled medication (i.e., controller vs. rescue medications).
- A list of other local asthma resources and smoking cessation resources (as appropriate) will be given to caregivers
- The nurse will provide colored medication labels to distinguish controller from rescue medications, following the action plan color scheme (green labels for controller medications, red labels for rescue medications). These labels will be applied to medications by the child/adolescent in clinic under nurse supervision.
- If medications are not filled in the Strong Outpatient Pharmacy and thus not available during the educational session, labels and instructions will be provided for patients to label medications at home. Care coordinators will follow-up with families to ensure appropriate labeling in this situation.
- Teach-back methods will be used to elicit understanding of correct indications of use for each medication (patient and caregiver).
- The nurse will demonstrate the technique for MDI medications using a spacer, with teach-back performed by both the patient and caregiver.
- They will discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility designed to reinforce the cooperative participation of both patients and caregivers.
- Patients will be asked to make a 1 month follow-up appointment for asthma care.
Care Coordination: Pediatric practice care coordinators will contact all enrolled patient families by telephone 1 week prior to the scheduled follow-up appointment. In addition to functioning as a personalized reminder of the upcoming appointment, this phone call will also allow care coordinators to identify any surmountable barriers to scheduled care and remind families to bring all of the child's asthma medications to the visit.
Follow-Up Assessments: The study, including all follow-up assessments, will continue until the end of the 2018 calendar year. After the baseline assessment, each patient will have two additional follow-ups. The first will be completed in clinic, approximately 1 month (~4-6 weeks) after the baseline visit. As all enrolled patients will have symptomatic or poorly controlled persistent asthma, this follow-up interval is appropriate and supported by NHLBI guidelines.(2) A brief follow-up survey will be conducted prior to the provider encounter, and will include a repeat assessment of key measures from the baseline assessment. Additional asthma education will be repeated at this clinic visit, with a specific emphasis on reinforcing both the medication teaching and the importance of dyadic co-management. Asthma medication refills will be delivered to clinic and labeled with stickers as necessary. The second follow-up will occur approximately 2 months after the follow-up clinic visit (3 months after baseline), and will be a semi-structured interview conducted over the phone by the research assistant.
In-depth Interviews: During the clinic follow-up, caregivers and children will be invited to separately participate in in-depth interviews before leaving clinic; this use of qualitative research methods will allow for an enhanced understanding of family behaviors around medication management. The interview guide will specifically explore respondent thoughts on medication identification, the parent-to-child transfer of responsibility for medication use, and the usefulness of different intervention components. Interviews will be conducted in clinic if possible or over the phone if necessary; audio recordings will be transcribed. Thematic analysis will be conducted on interview transcripts until theoretical saturation is achieved within each subgroup of child/adolescent ages.
Compensation: Each participating caregiver/child dyad will receive $25 after completion of the initial baseline assessment and clinic visit in the form of a prepaid debit card. Participants will be paid an additional $25 after each follow-up assessment (one in clinic, one by phone), and a final payment of $25 will be available for any dyads that decide to participate in optional qualitative data collection (in-depth interviews). After the telephone follow-up, payment will be sent via mail. Total payment will be no more than $100 per dyad.
- Conditions
- Asthma in Children
- Being tested
- Nurse-delivered education
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nurse-delivered educationOther
The nurse will:
- Give the caregiver and child an overview of asthma, and discuss asthma control, triggers, and medications.
- Give caregivers information about asthma management written at or below 6th grade reading levels.
- Provide colored medication labels to distinguish controller from rescue medications following the action plan color scheme (green for controller medications, red for rescue medications). Teach-back methods will be used to elicit understanding of correct indications of use.
- Demonstrate MDI/spacer technique with teach-back.
- Discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility.
- Ask patients to make a 1 month follow-up appointment for asthma care.
| Study group | Role | What they receive |
|---|---|---|
| Asthma education | Experimental | Not described Receives: Other: Nurse-delivered education |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in caregiver self-efficacy from baseline to 1 month and 3 month follow-up
Parent asthma self-efficacy scale. This is a 13 item survey tool with 2 subscales: attack prevention (questions 1-6) and attack management (questions 7-13). For each question about perceived ability to manage asthma, parents select responses from a 5 point Likert scale (with 1 representing 'not at all sure' and 5 representing 'completely sure'). Responses to items in each subscale are averaged together to generate a subscale score. Higher mean subscale scores indicated increasing parent ability to perform asthma management tasks.
Measured: Baseline, 1 month follow-up, 3 month follow-up
Change in child self-efficacy from baseline to 1 month and 3 month follow-up
Child asthma self-efficacy scale. This is a 14 item survey tool with 2 subscales: attack prevention (questions 1-8) and attack management (questions 9-14). For each question about perceived ability to manage asthma, children select responses from a 5 point Likert scale (with 1 representing 'not at all sure' and 5 representing 'completely sure'). Responses to items in each subscale are averaged together to generate a subscale score. Higher mean subscale scores indicated increasing child ability to perform asthma management tasks.
Measured: Baseline, 1 month follow-up, 3 month follow-up
Change in caregiver reported adherence from baseline to 1 month and 3 month follow-up
Caregiver interview about adherence with controller medication over the previous 2 weeks. We will ask about the number of controller medication doses missed over the previous 2 weeks. As many children are instructed to use controller medications twice every day (once in the morning and once at night), the number of missed doses of controller medication ranges from 0 to 28 doses.
Measured: Baseline, 1 month follow-up, 3 month follow-up
Change in child reported adherence from baseline to 1 month and 3 month follow-up
Child interview about adherence with controller medication over the previous 2 weeks. We will ask about the number of controller medication doses missed over the previous 2 weeks. As many children are instructed to use controller medications twice every day (once in the morning and once at night), the number of missed doses of controller medication ranges from 0 to 28 doses.
Measured: Baseline, 1 month follow-up, 3 month follow-up
Secondary outcomes (5)
Changes in caregiver report of symptom free days from baseline to 1 month and 3 month follow-up
We will ask how many full days (24 hours periods) that the patient was free of any asthma symptoms in the previous 2 weeks (range: 0-24 full days). A higher score indicates more days without symptoms.
Measured: Baseline, 1 month follow-up, 3 month follow-up
Changes in child report of symptom free days from baseline to 1 month and 3 month follow-up
We will ask how many full days (24 hours periods) that the patient was free of any asthma symptoms in the previous 2 weeks (range: 0-24 full days). A higher score indicates more days without symptoms.
Measured: Baseline, 1 month follow-up, 3 month follow-up
Changes in caregiver assessment of asthma control from baseline to 1 month and 3 month follow-up (children 12 years and older).
The asthma control test (ACT) is a validated asthma assessment tool for children and teens 12 years and older. This survey contains 5 questions, and assesses asthma symptoms over the previous 4 weeks. Answers range from 0 (indicating significant symptoms) to 5 (indicating no symptoms). The scale is interpreted through a sum score (range: 0-25 points), with a score of 20 points or higher indicating asthma control.
Measured: Baseline, 1 month follow-up, 3 month follow-up
Changes in child assessment of asthma control from baseline to 1 month and 3 month follow-up (children 12 years and older).
The asthma control test (ACT) is a validated asthma assessment tool for children and teens 12 years and older. This survey contains 5 questions, and assesses asthma symptoms over the previous 4 weeks. Answers range from 0 (indicating significant symptoms) to 5 (indicating no symptoms). The scale is interpreted through a sum score (range: 0-25 points), with a score of 20 points or higher indicating asthma control.
Measured: Baseline, 1 month follow-up, 3 month follow-up
Changes in caregiver and child asthma control from baseline to 1 month and 3 month follow-up (children ages 7-11 years)
The childhood asthma control test (cACT) is a validated asthma assessment tool for children 4 to 11 years old. This survey contains 7 questions, and assesses asthma symptoms over the previous 4 weeks. The first 4 questions about recent asthma symptoms are answered by children, with answers ranging from 0 (indicating significant symptoms) to 3 (indicating no symptoms). The final 3 questions are answered by parents, with answers ranging from 0 (indicating significant symptoms) to 5 (indicating no symptoms). The scale is interpreted through a sum score (range: 0-27 points), with a score of 20 points or higher indicating asthma control.
Measured: Baseline, 1 month follow-up, 3 month follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jan 2018
- Study start7 Jun 2018
- Primary completion31 May 2019
- Study completion30 Jun 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Asthma in ChildrenStudies of the same condition, open and under way.
- More trials run by University of RochesterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 44 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Rochester
- Sponsor type
- University, hospital or other
- Collaborators
- New York State Department of Health
- Responsible party
- Principal investigator, Sean Frey, University of Rochester
- Investigators
- Sean M Frey, MD, MPH, Principal investigator, University of Rochester
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03390556
- Sponsor's protocol ID
- RSRB00070365
- Status last verified
- Jul 2019
- First submitted
- 15 Dec 2017
- Last updated
- 23 Jul 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Promoting Partnership and Improving Self-Management for Children With Persistent Asthma: A Pilot Program of Clinic-Based Asthma Education and Medication Labeling
- ClinicalTrials.gov ID
- NCT03390556
- Acronym / sponsor ID
- RSRB00070365
- Conditions
- Asthma in Children
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 44 participants (actual)
- Lead sponsor
- University of RochesterUniversity, hospital or other
- Collaborators
- New York State Department of Health
- Study start
- 7 Jun 2018 (actual)
- Primary completion
- 31 May 2019 (actual)
- Study completion
- 30 Jun 2019 (actual)
- First posted
- 4 Jan 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to evaluate a pilot of clinic-based intervention of asthma education. After a scheduled outpatient encounter for well-child care or asthma care has concluded, a pediatric nurse will teach participants (children and their caregivers) about asthma, provide clearly written information about how to manage asthma, and discuss how to manage asthma at home with cooperation between caregivers and children. Families will also receive current asthma prescriptions in clinic, and colored labels will be attached to medications in order to match the color scheme of asthma action plans (green labels for controller medications, red labels for rescue medications). Families will be followed for 3 months after the first clinic visit, including a follow-up visit in clinic 1 month later and a follow-up telephone call 3 months after starting. The nurse will reinforce key educational points and review medication use at the follow-up clinic visit. Families will also be invited to complete an additional in-depth interview following the 1 month clinic follow-up. The investigator hypothesizes that knowledge, self-efficacy, and reported adherence with asthma medications will increase for both caregivers and children/adolescents following the intervention and labeling of delivered medications. In addition, the investigator hypothesizes that children/adolescents will have more symptom free days and improved control following the intervention.
Detailed description
Study Design:
The investigators propose a clinic-based intervention of asthma education and medication labeling to promote medication knowledge and self-efficacy for adherence among both caregivers and children. Approximately 40 children with uncontrolled persistent asthma and their caregivers will be enrolled prior to outpatient visits for asthma care (well child care or asthma-specific visits; total of 80 participants). After the scheduled encounter with a provider has concluded, enrolled dyads will receive an intervention of nurse-delivered asthma education and medication labeling. Dyads will then be followed prospectively for 3 months after the index visit. This follow-up period will include a clinic-based follow-up with a repeat of the intervention (1 month after enrollment, consistent with the follow-up interval suggested by national guidelines for uncontrolled asthma) and a second follow-up by telephone (2 months after clinic follow-up). Families will be invited to complete an additional in-depth interview following the 1 month clinic follow-up.
Subjects and Setting:
Children and adolescents 7-14 years of age will be screened for eligibility at a single ambulatory care location: the Golisano Children's Hospital Pediatric Practice, a National Committee for Quality Assurance (NCQA) accredited patient centered medical home (PCMH) in urban Rochester, New York. The investigators plan to enroll a convenience sample of 40 dyads of caregivers/children (total of 80 subjects) over an 8 month period. Children and adolescents will be enrolled equally from two age-based categories (7-10 years, 11-14 years). The range of child/adolescent ages is intended to select families with a range of shared responsibility for asthma medication use between the caregiver and child/adolescent. Some children independently use medications as early as six years old. On average, children bear half of the responsibility for controller medication use by age 11 years and have more responsibility than caregivers after age 13 years. Given these data, the specified age-based sub-groups are structured to reflect family dynamics in which children have <50% of responsibility for medications (7-10 years old) and ≥50% of responsibility for medications (11-14 years).
Study Procedures:
Screening Procedures: Screening will occur in a rolling fashion from January 2018 through August 2018. The investigators will identify potentially eligible children through a weekly review of pediatric clinic patients ages 7-14 years old who are (1) scheduled for well-child or asthma care over the following week, (2) have persistent asthma on their problem list, (3) have a current (within the last year) prescription for an inhaled controller medication, and (4) are covered by Medication or a Medicaid managed care program. After the reports are furnished, Dr. Frey will conduct a brief review of the patient's chart to determine whether key eligibility criteria are met (no known language barriers, no other significant medical or developmental conditions). Remaining eligibility criteria (i.e. determination of persistent/uncontrolled asthma per NHLBI guidelines) will be assessed during a single screening phone call prior to the scheduled visit, or by approaching caregivers at the time of scheduled visits if we are unable to reach caregivers by phone.
Baseline Assessment: The baseline survey assessment will be conducted following enrollment by the team research assistant within a private space in the clinic. All survey instruments will be available in English, and questions will be read aloud to the caregiver and child. If the baseline semi-structured survey is not completed before the provider encounter, caregivers will be given the option to complete the baseline either (a) before leaving clinic, or (b) over the telephone; completion in the clinic will be preferred so that children/adolescents can be separately interviewed in the presence of their caregivers.
Medication Selection and Delivery: Providers will be notified that their patients are enrolled into the program, and will be tasked with determining whether any changes in daily controller medications are indicated. The provider will electronically transmit prescriptions for both rescue and controller medications to the Strong Outpatient Pharmacy, located within the same building as the Pediatric Practice. All asthma prescriptions will be filled at this pharmacy during the trial in order to ensure that medications will be available for labeling in clinic, and parents will be informed of this during the consent process. The research assistant will call the pharmacy to notify them of new prescriptions; once these asthma prescriptions are filled, they pharmacy will send them to the Pediatrics Practice via the institution's pneumatic tube system. Any prescription medications that are not directly related to asthma management (including adjuvant therapies for allergic rhinitis) would be sent to the pharmacy of their choosing for normal processing and patient pick-up.
Nurse-delivered Education: The nurse will give the educational intervention after the provider encounter concludes. Nurses will be trained in intervention delivery and national asthma guidelines by Dr. Frey and Cindy Trubisky, Senior Director of Health Education for the American Lung Association (ALA) in Rochester, NY. This intervention will be directed toward both the caregiver and the child.
- The nurse will give the parent and child a brief, scripted overview of asthma, and discuss asthma control, asthma triggers, and indications for using inhaled controller vs. rescue medications.
- Parents will be given simple, written information about asthma and asthma management designed for low health-literacy audiences, specifically written at or below 6th grade reading levels, including:
- Information on appropriate metered dose inhaler (MDI)/ spacer technique
- An updated asthma action plan, with clear indications for when to use each inhaled medication (i.e., controller vs. rescue medications).
- A list of other local asthma resources and smoking cessation resources (as appropriate) will be given to caregivers
- The nurse will provide colored medication labels to distinguish controller from rescue medications, following the action plan color scheme (green labels for controller medications, red labels for rescue medications). These labels will be applied to medications by the child/adolescent in clinic under nurse supervision.
- If medications are not filled in the Strong Outpatient Pharmacy and thus not available during the educational session, labels and instructions will be provided for patients to label medications at home. Care coordinators will follow-up with families to ensure appropriate labeling in this situation.
- Teach-back methods will be used to elicit understanding of correct indications of use for each medication (patient and caregiver).
- The nurse will demonstrate the technique for MDI medications using a spacer, with teach-back performed by both the patient and caregiver.
- They will discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility designed to reinforce the cooperative participation of both patients and caregivers.
- Patients will be asked to make a 1 month follow-up appointment for asthma care.
Care Coordination: Pediatric practice care coordinators will contact all enrolled patient families by telephone 1 week prior to the scheduled follow-up appointment. In addition to functioning as a personalized reminder of the upcoming appointment, this phone call will also allow care coordinators to identify any surmountable barriers to scheduled care and remind families to bring all of the child's asthma medications to the visit.
Follow-Up Assessments: The study, including all follow-up assessments, will continue until the end of the 2018 calendar year. After the baseline assessment, each patient will have two additional follow-ups. The first will be completed in clinic, approximately 1 month (~4-6 weeks) after the baseline visit. As all enrolled patients will have symptomatic or poorly controlled persistent asthma, this follow-up interval is appropriate and supported by NHLBI guidelines.(2) A brief follow-up survey will be conducted prior to the provider encounter, and will include a repeat assessment of key measures from the baseline assessment. Additional asthma education will be repeated at this clinic visit, with a specific emphasis on reinforcing both the medication teaching and the importance of dyadic co-management. Asthma medication refills will be delivered to clinic and labeled with stickers as necessary. The second follow-up will occur approximately 2 months after the follow-up clinic visit (3 months after baseline), and will be a semi-structured interview conducted over the phone by the research assistant.
In-depth Interviews: During the clinic follow-up, caregivers and children will be invited to separately participate in in-depth interviews before leaving clinic; this use of qualitative research methods will allow for an enhanced understanding of family behaviors around medication management. The interview guide will specifically explore respondent thoughts on medication identification, the parent-to-child transfer of responsibility for medication use, and the usefulness of different intervention components. Interviews will be conducted in clinic if possible or over the phone if necessary; audio recordings will be transcribed. Thematic analysis will be conducted on interview transcripts until theoretical saturation is achieved within each subgroup of child/adolescent ages.
Compensation: Each participating caregiver/child dyad will receive $25 after completion of the initial baseline assessment and clinic visit in the form of a prepaid debit card. Participants will be paid an additional $25 after each follow-up assessment (one in clinic, one by phone), and a final payment of $25 will be available for any dyads that decide to participate in optional qualitative data collection (in-depth interviews). After the telephone follow-up, payment will be sent via mail. Total payment will be no more than $100 per dyad.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Asthma education | Experimental | Other: Nurse-delivered education |
Who may qualify
- Ages
- 7 to 14 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Physician diagnosis of asthma, based on review of medical records.
- Uncontrolled asthma consistent with National Heart, Lung, and Blood Institute (NHLBI) guidelines, with at least 1 of the following based on caregiver report:
- The child must have a current prescription (within the past year) of an inhaled asthma controller medication, such as an inhaled corticosteroid (ICS), based on review of electronic medical records.
- The child/adolescent is between ≥7 and ≤14 years old.
- The child/adolescent is insured by Medicaid or Medicaid managed care program.
Key exclusion criteria (5 listed)
- An inability to speak and understand English. Parents and children with low literacy / health-literacy skills will be eligible, as survey instruments will be administered verbally and educational materials will be designed for low-literacy populations.
- No access to a working phone for follow-up, including care coordinator calls and the final follow-up survey.
- Another significant medical condition identified in the child's medical record that could interfere with assessment of asthma control, including Cystic Fibrosis, congenital heart disease, or other chronic pulmonary disease.
- A diagnosed developmental condition (e.g. Autism spectrum disorder or significant developmental delay) identified in the child's medical record that could impact the transition of responsibility for inhaled asthma medications from caregiver to child.
- If the child or family is currently enrolled in a study conducted by The Preventive Care Program for Urban Children with Asthma (led by Dr. Jill Halterman).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nurse-delivered educationThe nurse will: 1. Give the caregiver and child an overview of asthma, and discuss asthma control, triggers, and medications. 2. Give caregivers information about asthma management written at or below 6th grade reading levels. 3. Provide colored medication labels to distinguish controller from rescue medications following the action plan color scheme (green for controller medications, red for rescue medications). Teach-back methods will be used to elicit understanding of correct indications of use. 4. Demonstrate MDI/spacer technique with teach-back. 5. Discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility. 6. Ask patients to make a 1 month follow-up appointment for asthma care. | Other | Asthma education |
Primary outcome
Change in caregiver self-efficacy from baseline to 1 month and 3 month follow-up
Time frame: Baseline, 1 month follow-up, 3 month follow-up
Parent asthma self-efficacy scale. This is a 13 item survey tool with 2 subscales: attack prevention (questions 1-6) and attack management (questions 7-13). For each question about perceived ability to manage asthma, parents select responses from a 5 point Likert scale (with 1 representing 'not at all sure' and 5 representing 'completely sure'). Responses to items in each subscale are averaged together to generate a subscale score. Higher mean subscale scores indicated increasing parent ability to perform asthma management tasks.
Change in child self-efficacy from baseline to 1 month and 3 month follow-up
Time frame: Baseline, 1 month follow-up, 3 month follow-up
Child asthma self-efficacy scale. This is a 14 item survey tool with 2 subscales: attack prevention (questions 1-8) and attack management (questions 9-14). For each question about perceived ability to manage asthma, children select responses from a 5 point Likert scale (with 1 representing 'not at all sure' and 5 representing 'completely sure'). Responses to items in each subscale are averaged together to generate a subscale score. Higher mean subscale scores indicated increasing child ability to perform asthma management tasks.
Change in caregiver reported adherence from baseline to 1 month and 3 month follow-up
Time frame: Baseline, 1 month follow-up, 3 month follow-up
Caregiver interview about adherence with controller medication over the previous 2 weeks. We will ask about the number of controller medication doses missed over the previous 2 weeks. As many children are instructed to use controller medications twice every day (once in the morning and once at night), the number of missed doses of controller medication ranges from 0 to 28 doses.
Change in child reported adherence from baseline to 1 month and 3 month follow-up
Time frame: Baseline, 1 month follow-up, 3 month follow-up
Child interview about adherence with controller medication over the previous 2 weeks. We will ask about the number of controller medication doses missed over the previous 2 weeks. As many children are instructed to use controller medications twice every day (once in the morning and once at night), the number of missed doses of controller medication ranges from 0 to 28 doses.
5 secondary outcomes
Changes in caregiver report of symptom free days from baseline to 1 month and 3 month follow-up
Time frame: Baseline, 1 month follow-up, 3 month follow-up
Changes in child report of symptom free days from baseline to 1 month and 3 month follow-up
Time frame: Baseline, 1 month follow-up, 3 month follow-up
Changes in caregiver assessment of asthma control from baseline to 1 month and 3 month follow-up (children 12 years and older).
Time frame: Baseline, 1 month follow-up, 3 month follow-up
Changes in child assessment of asthma control from baseline to 1 month and 3 month follow-up (children 12 years and older).
Time frame: Baseline, 1 month follow-up, 3 month follow-up
Changes in caregiver and child asthma control from baseline to 1 month and 3 month follow-up (children ages 7-11 years)
Time frame: Baseline, 1 month follow-up, 3 month follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2019.
- Individual participant dataSharing planned: No
Related trials for Asthma in Children
Not yet recruiting
Bilevel Positive Airway Pressure (BPAP) for Severe Asthma
Pediatric Asthma, Acute Asthma
Not yet recruiting
Artificially Intelligent Robot Control
Asthma in Children, Artificial Intelligence
Enrolling by invitationObservational study
Investigating Novel Strategies in Pediatric Immune Responses and Microbiome Environment: Comprehensive Lung Disease Investigation in Children.
Lung Diseases
Recruiting
Effects of Tele-rehabilitation-Guided Qigong on Children and Adolescents With Asthma
Asthma Childhood
Enrolling by invitationObservational study
Allergy, Asthma, and Atopic Eczema in Finland
Asthma, Asthma in Children
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sean M Frey, MD, MPH principal investigator
University of Rochester
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nurse-delivered education in people with Asthma in Children, run by University of Rochester at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in caregiver self-efficacy from baseline to 1 month and 3 month follow-up (time frame: Baseline, 1 month follow-up, 3 month follow-up). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2019.